278 related articles for article (PubMed ID: 26243735)
61. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
62. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
63. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
64. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
65. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
[TBL] [Abstract][Full Text] [Related]
66. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Sakkas LI; Mavropoulos A; Bogdanos DP
Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.
Tsiogkas SG; Karamitrou EK; Grammatikopoulou MG; Zafiriou E; Bogdanos DP
Curr Med Res Opin; 2024 Feb; 40(2):155-163. PubMed ID: 37997745
[TBL] [Abstract][Full Text] [Related]
68. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
69. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Bagel J; Nelson E; Keegan BR
J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
[TBL] [Abstract][Full Text] [Related]
70. Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
Harrison C
Nat Rev Drug Discov; 2013 May; 12(5):335. PubMed ID: 23629496
[No Abstract] [Full Text] [Related]
71. Apremilast in psoriasis - a prospective real-world study.
Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
[TBL] [Abstract][Full Text] [Related]
72. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A; Rich P; Sofen H; Strober B; Merola JF; Lebwohl M; Morita A; Szepietowski JC; Lambert J; Hippeli L; Colston E; Balagula E; Banerjee S; Thaçi D
J Am Acad Dermatol; 2024 Apr; 90(4):775-782. PubMed ID: 38122848
[TBL] [Abstract][Full Text] [Related]
73. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Schafer PH; Chen P; Fang L; Wang A; Chopra R
J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
[TBL] [Abstract][Full Text] [Related]
74. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
[TBL] [Abstract][Full Text] [Related]
75. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
[TBL] [Abstract][Full Text] [Related]
76. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
[TBL] [Abstract][Full Text] [Related]
77.
Liadaki K; Zafiriou E; Giannoulis T; Alexouda S; Chaidaki K; Gidarokosta P; Roussaki-Schulze AV; Tsiogkas SG; Daponte A; Mamuris Z; Bogdanos DP; Moschonas NK; Sarafidou T
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540428
[TBL] [Abstract][Full Text] [Related]
78. Emerging oral drugs for psoriasis.
Mahmood T; Zaghi D; Menter A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):209-20. PubMed ID: 25643592
[TBL] [Abstract][Full Text] [Related]
79. The Use of Apremilast to Treat Psoriasis During Deployment.
Rosenberg A; Meyerle J
Mil Med; 2017 Jul; 182(7):1628-1631. PubMed ID: 28810954
[TBL] [Abstract][Full Text] [Related]
80. Apremilast (otezla) for psoriatic arthritis.
Med Lett Drugs Ther; 2014 May; 56(1443):41-2. PubMed ID: 24869713
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]